Regulating the response to targeted MEK inhibition in melanoma: Enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation

Cell Cycle

Volumn 11, Issue 20, 2012, Pages 3724-3730

  Conrad, William H ^a,b   Swift, Reyna D ^a   Biechele, Travis L ^a   Kulikauskas, Rima M ^a   Moon, Randall T ^a,b   Chien, Andy J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; BRAF; MEK; Melanoma; Wnt

Indexed keywords

EID: 84868019680     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21645     Document Type: Article

References (44)

1. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006;355:51-65; PMID:16822996; http://dx.doi.org/10.1056/NEJMra052166.
2. Cancer Facts & Figures 2011.
3. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LAG, Eheman C, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011;103:714-36; PMID:21454908; http://dx.doi.org/10.1093/jnci/djr077.
4. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9; PMID:20823850; http://dx.doi.org/10.1038/nature09454.
5. Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010;23:820-7; PMID:20973932; http://dx.doi.org/10.1111/j.1755-148X.2010.00763.x.
6. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of onco-genic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105:3041-6; PMID:18287029; http://dx.doi.org/10.1073/pn a s. 0 711741105. (Pubitemid 351723664)
7. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204(PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010;70:5518-27; PMID:20551065; http://dx.doi.org/10.1158/0008-5472. CAN-10-0646.
8. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Current Protocols in Human Genetics/Editorial Board, Jonathan L Haines [et Al] 2008; Chapter 10:Unit 10.1-Unit. 1.
9. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2010;39:945-50.
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782.
11. Flaherty K T, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011.
12. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14; PMID:22356324; http://dx.doi.org/10.1056/NEJMoa1112302.
13. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol 2009;129:1614-27; PMID:19177135; http://dx.doi.org/ 10.1038/jid.2008.445.
14. Dorsky RI, Moon RT, Raible DW. Control of neural crest cell fate by the Wnt signalling pathway. Nature 1998;396:370-3; PMID:9845073; http://dx.doi.org/10.1038/24620. (Pubitemid 28557397)
15. Dorsky RI, Moon RT, Raible DW. Environmental signals and cell fate specification in premigra-tory neural crest. Bioessays 2000;22:708-16; PMID:10918301; http://dx.doi.org/10.1002/1521-1878 (200008) 22:8<708::AID- BIES4>3.0. CO;2-N. (Pubitemid 30613302)
16. Dorsky RI, Raible DW, Moon RT. Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. Genes Dev 2000;14:158-62; PMID:10652270. (Pubitemid 30070981)
17. Larue L, Kumasaka M, Goding CR. Beta-catenin in the melanocyte lineage. Pigment Cell Res 2003;16:312-7; PMID:12753406; http://dx.doi.org/10.1034/j.1600- 0749.2003.00050.x. (Pubitemid 36597073)
18. Vance K W, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 2004;17:318-25; PMID:15250933;http:// dx.doi.org/10.1111/j.1600-0749.2004.00164.x. (Pubitemid 38993061)
19. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 2005;11:8606-14; PMID:16361544;http://dx.doi.org/10.1158/1078-0432. CCR-05-0011. (Pubitemid 43005907)
20. Kageshita T, Hamby CV, Ishihara T, Matsumoto K, Saida T, Ono T. Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 2001;145:210-6; PMID:11531781; http://dx.doi.org/10. 1046/j.1365-2133.2001.04336.x. (Pubitemid 32955344)
21. Maelandsmo GM, Holm R, Nesland JM, Fodstad O, Flørenes VA. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 2003;9:3383-8; PMID:12960126. (Pubitemid 37082733)
22. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci USA 2009;106:1193-8; PMID:19144919; http://dx.doi.org/10.1073/pnas. 0811902106.
23. Meyer S, Fuchs TJ, Bosserhoff AK, Hofstädter F, Pauer A, Roth V, et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS ONE 2012;7:e38222; PMID:22685558; http://dx.doi.org/10.1371/jour-nal.pone. 0038222.
24. Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, et al. Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 2012;5:ra3; PMID:22234612; http://dx.doi.org/10.1126/scisig-nal.2002274.
25. Lee E, Salic A, Krüger R, Heinrich R, Kirschner M W. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol 2003;1:E10; PMID:14551908; http://dx.doi.org/10.1371/journal. pbio.0000010. (Pubitemid 39112198)
26. Salic A, Lee E, Mayer L, Kirschner MW. Control of beta-catenin stability: reconstitution of the cytoplas-mic steps of the wnt pathway in Xenopus egg extracts. Mol Cell 2000;5:523-32; PMID:10882137; http://dx.doi.org/10.1016/ S1097-2765 (00) 80446-3.
27. Willert K, Shibamoto S, Nusse R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev 1999;13:1768-73; PMID:10421629; http://dx.doi.org/10.1101/gad.13.14.1768. (Pubitemid 29353044)
28. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3β regulates its stability. J Biol Chem 1999;274:10681-4; PMID:10196136; http://dx.doi.org/10.1074/jbc.274.16.10681. (Pubitemid 29191041)
29. Cha B, Kim W, Kim YK, Hwang BN, Park SY, Yoon J W, et al. Methylation by protein arginine methyltransferase 1 increases stability of Axin, a negative regulator of Wnt signaling. Oncogene 2011;30:2379-89; PMID:21242974; http://dx.doi.org/10.1038/onc.2010.610.
30. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 2009;34:115-31; PMID:19362540; http://dx.doi.org/10.1016/j.molcel. 2009.03.007.
31. Kim MJ, Chia I V, Costantini F. SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability. FASEB J 2008;22:3785-94; PMID:18632848; http://dx.doi.org/10.1096/fj.08-113910.
32. Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, et al. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS ONE 2011;6:e22595; PMID:21799911; http://dx.doi.org/10.1371/journal.pone.0022595.
33. Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA, et al. RNF146 is a poly (ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol 2011;13:623-9; PMID:21478859; http://dx.doi.org/ 10.1038/ncb2222.
34. Lui TTH, Lacroix C, Ahmed SM, Goldenberg SJ, Leach CA, Daulat AM, et al. The ubiquitin-specific protease USP34 regulates axin stability and Wnt/β-catenin signaling. Mol Cell Biol 2011;31:2053-65; PMID:21383061; http://dx.doi.org/10.1128/MCB.01094-10.
35. Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M, et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 2007;21:2923-35; PMID:18006687; http://dx.doi.org/10.1101/gad.450107. (Pubitemid 350133440)
36. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, et al. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011;20:741-54; PMID:22172720; http://dx.doi.org/10.1016/j.ccr.2011.10.030.
37. Omholt K, Platz A, Ringborg U, Hansson J. Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer 2001;92:839-42; PMID:11351304; http://dx.doi.org/10.1002/ijc.1270. (Pubitemid 32467373)
38. Pollock PM, Hayward N. Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines. Melanoma Res 2002;12:183-6; PMID:11930117; http://dx.doi.org/10.1097/00008390-200204000-00013. (Pubitemid 34478461)
39. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999;154:325-9; PMID:10027390; http://dx.doi.org/10.1016/S0002-9440 (10) 65278-9. (Pubitemid 29094082)
40. Hou P, Liu D, Dong J, Xing M. The BRAF (V600E) causes widespread alterations in gene methyla-tion in the genome of melanoma cells. Cell Cycle 2012;11:286-95; PMID:22189819; http://dx.doi.org/10.4161/cc.11.2.18707.
41. Genovese G, Ghosh P, Li H, Rettino A, Sioletic S, Cittadini A, et al. The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells. Cell Cycle 2012;11:2206-15; PMID:22647378; http://dx.doi.org/10.4161/cc.20765.
42. Namiki T, Coelho SG, Hearing VJ. NUAK2: an emerging acral melanoma oncogene. Oncotarget 2011;2:695-704; PMID:21911917.
43. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009;33:237-47; PMID:19187764; http://dx.doi.org/10.1016/j. molcel.2008.12.026.
44. Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2011;2:336-46; PMID:21505228.